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Abstract 
52
Mn (t1/2 =5.59 d, ß
+
 = 29.6%, Eßave = 0.24 MeV) shows promise in positron emission tomography (PET) and in 
dual-modality manganese-enhanced magnetic resonance imaging (MEMRI) applications including neural 
tractography, stem cell tracking, and biological toxicity studies. The extension to bioconjugate application 
requires high specific activity 
52
Mn in a state suitable for macromolecule labeling. To that end a 
52
Mn production, 
purification, and labeling system is presented, and its applicability in preclinical, macromolecule PET is shown 
using the conjugate 
52
Mn-DOTA-TRC105. 
52
Mn is produced by 60 µA, 16 MeV proton irradiation of natural 
chromium metal pressed into a silver disc support. Radiochemical separation proceeds by strong anion exchange 
chromatography of the dissolved Cr target, employing a semi-organic mobile phase, 97:3 (v:v) ethanol: HCl 
(11M, aqueous). The method is 62 ± 14% efficient (n=7) in 
52
Mn recovery, leading to a separation factor from Cr 
of (1.6 ± 1.0) x10
6
 (n = 4), and an average effective specific activity of 0.8 GBq/µmol (n = 4) in titration against 
DOTA. 
52
Mn-DOTA-TRC105 conjugation and labeling demonstrate the potential for chelation applications. In 
vivo images acquired using PET/CT in mice bearing 4T1 xenograft tumors are presented. Peak tumor uptake is 
18.7 ± 2.7 %ID/g at 24 hours post injection and ex vivo 
52
Mn biodistribution validates the in vivo PET data. Free 
52
Mn
2+ 
(as chloride or acetate) is used as a control in additional mice to evaluate the non-targeted biodistribution 
in the tumor model. 
 
Keywords 
Positron emission tomography (PET), immunoPET, manganese-52 (Mn-52, 52Mn), CD105/Endoglin, Tumor angiogenesis, TRC105, 
molecular imaging, DOTA chelation, organic anion exchange, trace metal analysis (MP-AES, ICP-OES) 
 
Introduction 
Interest in 
52
Mn
1
-based positron emission 
tomography (PET) applications has increased 
dramatically in recent years partly due to PET/MRI 
technological advancements and partly due to 
increased demand for long-lived PET radiometals 
such as 
64
Cu and 
89
Zr.
1, 2
 For MRI, the T1-shortening 
                                                          
1
 Throughout the text 
52
Mn refers to the ground state 
nuclide,
52g
Mn, rather than the short-lived isomer 
52m
Mn. 
properties of bulk manganese are employed in 
manganese-enhanced magnetic resonance imaging 
(MEMRI). However, the biological toxicity of bulk 
manganese
3
 has hampered the development and 
progression of otherwise useful applications such as 
diffusion-tensor neuronal fiber tractography
4-6
, 
nociceptive activity detection
7
, functional imaging of 
brain activation
8
, diagnosis and staging of pancreatic 
cancer
9
, heptocellular carcinoma detection
10
, cell 
tracking
11, 12
 and evaluation of cardiac inotropic 
therapy
13
. Manganese-52-based PET tracer 
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alternatives may provide analogous data with lower 
toxicity and thereby promote clinical application.  
Additionally 
52
Mn may offer advantages 
over traditional 
64
Cu or 
89
Zr immunoPET in 
situations where treatment response monitoring at 
late time-points (2-3 weeks) is desired. In cases 
where radioimmunotherapy is initiated with long-
lived nuclides such as 
177
Lu, the full time-course of 
treatment could be monitored by 
52
Mn PET. Further, 
due to the abundance of coincident high energy 
gammas, 
52
Mn is one of relatively few nuclides that 
can be used in third-gamma coincidence PET for 
either event dual nuclide event tagging or combined 
Compton telescope PET tomography
14
. Despite this, 
clinical translation should proceed with caution due 
to the preponderance of coincident high energy 
gammas: 744 keV (90%), 935 keV (95%) and 1434 
keV (100%). Coupled with the myriad biological 
roles of manganese, which may lead to prolonged 
retention of radiomanganese in critical organs, 
careful dosimetry prior to translation should be 
considered.   
A common method for high-yield 
production of 
52
Mn is via the 
52
Cr(p,n) reaction: a 
route available using small biomedical cyclotrons
15-
18
. Due to the natural 83.8% abundance of 
52
Cr in 
nat
Cr and the low propensity for impurity formation 
of other Mn isotopes during proton irradiation, 
nat
Cr, 
which is available in high purity from various 
distributors, is an inexpensive alternative to enriched 
target material. The main radionuclidic impurity 
formed from the irradiation of 
nat
Cr is 
54
Mn (t1/2 = 
312 d) with an energy dependent co-production rate, 
representing 0.1-0.4% of the 
52
Mn activity at the end 
of a short bombardment at 16 MeV
16, 19
. For one 
hour 16 MeV irradiations on a thick Cr target, the 
expected yield of 
52
Mn is approximately 9.5 
MBq/µA
19
. 
 In order to separate 
52
Mn from the bulk Cr 
matrix, anion exchange from semi-aqueous 
hydrochloric acid media is a simple trap-and release 
technique. Previously published methods for 
separating manganese from chromium involving 
anion exchange
 
rely upon the formation of anionic 
chloride complexes of manganese
17, 18, 20
.  Notably, 
there is a marked enhancement in the formation of 
the anionic manganese chlorides when hydration is 
limited by using non-aqueous solvents
21
. However, 
under similar conditions Cr
3+
 does not form anionic 
chloride complexes. This behavior is evident in the 
distribution coefficients for Mn and Cr against anion 
exchange resin from 97% EtOH 0.3M HCl 
solutions
21
, where the resin affinities are sufficiently 
disparate for trap-and-release purification of 
52
Mn 
from bulk Cr with small resin beds.  
As a first test for bifunctional chelation of 
Mn to macromolecules, the common chelate DOTA 
(1,4,7,10 tetraazacyclododecane 1,4,7,10 tetraacetic 
acid) is an obvious choice due to its ubiquity in 
radiochemical applications and the reported stability 
of DOTA chelates with Mn(II)
22
. Because the long 
physical half-life of 
52
Mn (t1/2 = 5.591 days
23
)
 
lends 
itself well to the long biological circulation times in 
radioimmunoPET applications, a demonstration of 
the stable chelation of 
52
Mn using bifunctionalized 
DOTA  conjugated to a monoclonal antibody proves 
its usefulness as a radiotracer. For this study 
TRC105, a chimeric human/murine immunoglobulin 
G (IgG1) monoclonal antibody (mAb) which binds 
to the angiogenic marker CD105 with very high 
specificity, was chosen as the model compound due 
to the extensive body of data available that describes 
its biodistribution with other radiometals and 
chelates
24-26
. This antibody is currently associated 
with seventeen phase I and II multi-center clinical 
trials which are planned, underway, or already 
completed investigating the therapeutic efficacy in a 
variety of solid tumors either alone or as an adjunct 
to other treatment techniques.   
The purpose of this report is to describe a 
methodology for the production and purification of 
52
Mn that is amenable to bioconjugate chemistry. A 
simple cyclotron target made of chromium metal is 
described, and the procedure for extracting 
52
Mn 
from the Cr matrix is given. The chemical purity of 
the produced 
52
Mn is demonstrated by trace metal 
analysis and chelation with DOTA. Finally, the 
suitability of DOTA as a bifunctional chelate for Mn 
is investigated by in-vivo experiments of 
52
Mn-
DOTA-TRC105 in 4T1 xenograft-bearing mice, and 
comparison with the biodistribution of weakly 
coordinated 
52
Mn
2+
. To our knowledge, the 
formation of 
52
Mn-DOTA-TRC105 constitutes the 
first bioconjugate radiomanganese PET agent, and 
acts as a benchmark of the purity of 
52
Mn required 
for targeted PET. 
 
Results and Discussion 
 
Target Fabrication, Irradiation, Dissolution and 
Column Separation 
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The goal of creating a simple design for metal 
chromium irradiation was met by pressing high 
purity chromium with a hydraulic press into a silver 
backing at 30kN. The Cr/Ag pressed targets were 
remarkably resilient, withstanding 60 µA of 16 MeV 
protons for two hours without failure. An example 
target is shown in Figure 1. Based on the alloying 
behavior of chromium and silver
27
, we speculate that 
in addition to any mechanic bonding, 30 kN may be 
sufficient to form an eutectic alloy at the boundary 
between the two metals facilitating thermal 
conduction and physical stability. The average end-
of-bombardment 
52
Mn yield was  5 ± 1 MBq/µAh 
(n=12), which is approximately half of our 
previously measured thick target production rate of 
9.5±1 MBq/µAh
19
 due to target thickness 
irregularities and partial beam-spot coverage.  
 
 
 
Figure 1:  99.999% pure chromium pellet imbedded 
in silver, direct-jet watercooled on the rear target 
face, before (A) and after (B) irradiation by 60 µA of 
16 MeV protons for one hour.  
 
Following irradiation, targets were etched with HCl 
and the resulting solution was diluted with ethanol. 
This was done in order to reach a condition where 
dissolved Mn(II) anionic chloride complexes extract 
onto strong anion-exchange resin while hydrated 
Cr
3+
 passes through. Upon switching to a fully 
aqueous 6M HCl solution 
52
Mn was released from 
the resin bed. The entire procedure of trap-and-
release, alternating from ethanolic to aqueous 
mixtures was repeated three times on three separate 
small AG-1x8 columns. 
52
Mn extraction from ethanolic HCl onto 
AG-1x8 was 73 ± 13%, 91 ± 4%, and 92 ± 5% 
efficient (n=7) at each of the column passes. The 
low first-step separation efficiency is likely due to 
the low HCl and ethanol concentrations for loading, 
approximately 0.11 M and 95% respectively, 
compared to the ideal concentrations of >0.3 M HCl 
and >97% ethanol. It is likely that 
52
Mn trapping 
could be greatly improved by drying the dissolved 
target material before reconstituting in 0.3 M HCl, 
97% EtOH. Alternatively, a hydrogen chloride 
ethanol or dioxane solution (4.0 M HCl in dioxane, 
Sigma Aldrich Inc.) could be used after target 
dissolution to obtain the desired HCl concentration 
without the burden of added aqueous volume. The 
overall 
52
Mn recovery efficiency of 62 ± 14% (n=7) 
was sufficient for our purposes, as it was nearly 
twice as efficient as the previously reported 
trioctylamine based extraction approach to 
52
Mn/
nat
Cr separation
19
 and more easily lends itself 
to automation. 
Chromium content in the eluted fractions 
fell successively at each step by factors of 601 ± 31, 
80 ± 6, and 42 ± 5 (n=1), as seen in Table 1.  The 
overall chromium separation factor was 1.6x10
6
 ± 
1.0x10
6
 (n = 4) as measured by trace metal analysis. 
During the first column separation, the resin became 
uniformly green-tinted indicating a slight retention 
of Cr
3+
. This chromium did not wash off of the resin 
in any appreciable way with repeated rinses of the 
ethanolic HCl. However upon elution of 
52
Mn, this 
species of Cr also co-eluted to a small degree. 
Similar effects were observed in the other two 
subsequent column separations by tracing the Cr 
content with microwave plasma atomic emission 
spectrometry (MP-AES). Surprisingly this behavior 
contrasts with the published distribution coefficients 
of Pietrzyk et al., in that the extracted species of Cr 
was not behaving chromatographically
21
. This is 
ultimately the reason why three sequential 
separations were required to achieve the necessary 
purity for labeling, rather than repeated washings. 
The act of removing the Cr from the column and 
then re-constituting it in the ethanolic solutions 
appeared to reset the Cr form dichotomy, although 
with diminishing returns. This is likely due to the 
formation of different hydration states of Cr
3+
 in 
solution and their slow interchange
28
. Regardless, 
the two additional column repetitions were not 
restrictive to rapid isolation of the product 
52
Mn. 
 
Table 1. Stepwise chromium reduction in a single 
production batch quantified by MP-AES hold-back 
measurements. 
  
Cr Mass (µg) 
Step  
Separation 
Factor 
Cumulative  
Separation 
Factor 
Dissolved Target (4.05 ± 0.04) x103 - - 
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After Column #1 360 ± 18 601 ± 31 (6.0±0.3) x102 
After Column #2 3.82 ± 0.19 80 ± 6 (4.8 ± 0.4) x104 
After Column #3 0.083 ± 0.008 42 ± 5 (2.0 ± 0.3) x106 
 
Analysis of Purity: Chelation and Trace Metal 
Quantification 
Titration of the 
52
Mn sample against varying 
concentrations of DOTA resulted in an effective 
specific activity of up to 2GBq/µmol. MP-AES trace 
metal analysis of the final samples are given in 
Table 2. If all transition metal impurities are 
considered to be competitive for DOTA chelation, 
reactions at a level of about 4GBq/µmol are 
predicted from the data. It is probable that a 
significant portion of the trace metal impurities 
come from the large volumes of ethanol involved in 
the separation process. For example, we observed 
iron in the ethanol stock at a concentration of 31 
ng/mL, or roughly 5 µg total iron mass in a typical 
production. An additional in-house distillation of 
commercial ethanol might be effective in producing 
metal-free ethanol, reducing impurities in future 
52
Mn productions. 
 
Table 2:  Trace metal analysis by microwave plasma 
atomic emission spectrometry of the radiochemically 
separated 
52
Mn product from approximately 400 mg 
dissolved Cr target material in three independent 
separations (Runs 1-3). 
 
Element 
Run 1 
Mass (µg) 
Run 2 
Mass (µg) 
Run 3 
Mass (µg) 
Cr 1.07 ± 0.10 0.17 ± 0.02 0.11 ± 0.01 
Mn 0.11 ± 0.01 0.23 ± 0.05 0.19 ± 0.01 
Fe 0.19 ± 0.02 1.26 ± 0.17 0.72 ± 0.08 
Co 0.00 ± 0.01 0.00 ± 0.04 0.00 ± 0.15 
Ni 0.00 ± 0.01 0.56 ± 0.16 0.18 ± 0.01 
Cu 0.14 ± 0.01 0.04 ± 0.02 0.43 ± 0.06 
Zn 3.30 ± 0.33 1.78 ± 0.27 1.10 ± 0.23 
 
TRC105 conjugation, labeling, imaging, and 
biodistribution 
A lower average 
52
Mn-DOTA effective specific 
activity of 0.8 GBq/µmol compared to that of the 
typical 
89
Zr-DFO assay (~30 GBq/µmol) motivated 
an increase in the bifunctional-chelate to antibody 
ratio (25:1) during conjugation. The resulting 
DOTA-TRC105 had excellent radiolabeling 
properties as shown in Table 3. 4 µg/MBq of 
DOTA-TRC105 was sufficient to reach 
52
Mn 
complexation efficiencies greater than 95% after 60 
minutes at 37 °C 
 
Table 3: Radiolabeling efficiency of 
52
Mn-DOTA-
TRC105 as a function of antibody mass and time as 
measured by thin layer chromatography. Reactions 
took place at 37 °C in a pH 4.0-4.5 NaOAc buffered 
solution.  
mAb mass 
(µg/MBq) 
 
20 min 
 
40 min 
 
60 min 
2.7 85% 89% 95% 
6.8 98% 93% 99% 
13.5 99% 95% 98% 
27.0 99% 93% 100% 
 
Injections of 
52
Mn-DOTA-TRC105 were 
administered to Balb/c mice bearing 4T1 xenografts 
and PET data were collected. Maximum intensity 
projection (MIP) PET images are shown in Figure 2. 
ROI quantification of the 
52
Mn-DOTA-TRC105 PET 
images yielded the time activity curves shown in 
Figure 3. Finally, the ex vivo biodistribution results 
shown in Figure 4 confirm the accuracy of image-
based ROI quantification. 
Tumor uptake peaked at the 24-hour PET 
time-point with an average value of 19 ± 3 %ID/g 
(n=3). The 
52
Mn-DOTA-TRC105 time activity 
curves measured in this work agree well with those 
seen with 
89
Zr-labeled TRC105 via desferrioxamine 
in the same animal and xenograft model
25
 indicating 
a stable conjugate. Furthermore the increased DOTA 
conjugation ratio does not seem to perturb CD105 
binding affinity. When comparing the ex vivo 
biodistribution of 
89
Zr-DF-TRC105 to 
52
Mn-DOTA-
TRC105 the most significant difference is the slower 
blood clearance rate of 
52
Mn-DOTA-TRC105 to 
89
Zr-Df-TRC105. Assuming the same conjugate 
distribution, dosimetrically, 
52
Mn is less favorable 
for injection compared to 
89
Zr for immunoPET (see 
Supporting Information). However in some 
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instances the higher dose from 
52
Mn may be justified 
for longer-term scanning, or its use in novel triple 
coincidence PET cameras. 
 
Figure 2:  Serial maximum intensity projection (MIP) PET images of mice injected with 
52
Mn-DOTA-TRC105 
and 
52
MnCl2. Significant thyroid accumulation in the 
52
MnCl2 images contrasting the lack of uptake in the 
52
Mn-
DOTA-TRC105 images indicates highly stable DOTA chelation of 
52
Mn
2+
 even at late time-points. Note – H: 
Heart, L: Liver, K: Kidneys, T: Tumor, Th: Thyroid. 
Comparing 
52
Mn-DOTA-TRC105 with the “Free 
52
Mn”2 PET images, there are clear differences in the 
                                                          
2
 No qualitative differences were observed between subjects 
injected with 52MnCl2 (n=2) vs 
52Mn-Acetate (n=2), suggesting 
 
distribution pattern. The most pronounced 
differences include a lack of thyroid uptake in the 
52
Mn-DOTA-TRC105 images, and a lack of tumor 
                                                                                              
rapid ionic dissociation post-injection. These four subjects were 
therefore combined into a single “Free 52Mn” group. 
52Mn-DOTA-TRC105
30 %ID/g
1 %ID/g
4 h 24 h 48 h 72 h 120 h 
T
H
L
K
20 %ID/g
1 %ID/g
4 h 24 h 48 h 60 h 96 h 
Th
T
H
L
K
Free 52Mn
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uptake in the 
52
MnCl2 images. These features 
support that the DOTA chelation of 
52
Mn is stable, 
even 120 hours post-injection. However, there is an 
enhanced signal in the bones with the targeted 
injections, but not in the free-ion case. Typically 
bone uptake in immunoPET is associated with 
instability of the metal-chelate pair. If this is the case 
in the present study, it is clear that the slow-
dissociating manganese displays a pharmacokinetic 
profile that is distinct from the free manganese. One 
possible explanation is a direct interaction between 
the bone and the DOTA-bound manganese rather 
than a hydrolysis mechanism for chelate instability. 
Further investigation into the in vivo behavior of 
manganese salts may help determine the impact that 
slow dissociation has upon PET quantification, as 
has been done for 
89
Zr.
29
 
 
Impurities 
Prior to translation there are many important 
considerations, especially concerning radionuclidic 
and chemical purity. The injections in this study 
contained approximately 0.5% radionuclidic 
impurity from 
54
Mn, which contributes only in a 
small way to personal dosimetry (see Supporting 
Information), but the long half-life (biological and 
physical) may be an important factor in deciding 
whether or not to use enriched 
52
Cr as an alternative 
target material: thereby eliminating production of 
54
Mn. Chemically, the use of chromium in a 
pharmaceutical production may raise concerns of 
toxic effects. However, the amount of Cr that 
remains after purification is extremely low, at most 
1µg for an entire production (150-250MBq). This Cr 
has no propensity to form a stable complex with 
functionalized DOTA
30
 and would be further 
removed during the size-exclusion purification step. 
For comparison, the EPA reference dose, RfD, for 
Cr(IV), below which no effects are observed is 
3µg/kg in rats
31
: a level much higher than would be 
reached following injection of a purified 
52
Mn-
immunoconjugate.  
  
 
 
 
Figure 3:  Time activity curves (TACs) acquired 
from ROI analysis of PET images obtained in 
subjects injected with 
52
Mn-DOTA-TRC105 (n = 3) 
and with Free 
52
Mn (n = 4). Error bars represent the 
standard deviation, and are displayed one-sided for 
visual clarity. The Heart/Blood TAC uses an ROI 
drawn over the left ventricle and does not 
differentiate myocardium from the blood pool.  
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Figure 4:  Ex vivo 
52
Mn-DOTA-TRC105 (n = 3) and 
52
MnCl2/
52
Mn-acetate (n = 4) biodistribution data 
obtained following the last PET time point. Animals 
were sacrificed, and tissue samples were isolated, 
washed with saline, dried, weighed, and gamma 
counted.  
 
Conclusion 
 
The results above and methodology below are 
intended to provide an easily reproducible path 
towards investigating bioconjugate systems using 
52
Mn. The example of 
52
Mn-DOTA-TRC105 shows 
that stable chelation of manganese via 
bifunctionalized DOTA is suitable for tracing 
macromolecules with PET over the course of several 
days, with imaging characteristics that compare 
favorably to 
89
Zr. Additionally, the effective specific 
activity of 
52
Mn that results from anion-exchange 
separations from ethanol-HCl mixtures is sufficient 
to conduct antibody imaging.  
 
Experimental Procedures 
 
Materials 
All reagents were obtained from commercial 
vendors and were used as received unless otherwise 
stated. TRC105 (mAb) was provided by TRACON 
Pharmaceuticals Inc. 4T1 murine breast cancer cells 
were obtained from the American Type Culture 
Collection (ATCC). Aqueous solutions were 
constituted in >18 MΩ/cm water. Unless noted, the 
term HCl refers to 32-35% aqueous hydrochloric 
acid Ethanol-HCl mixtures were made in v:v 
proportion using ethanol (molecular biology grade, 
Sigma Aldrich) and 32-35% aqueous HCl 
(untitrated, Optima grade, VWR). 
 
Target Fabrication, Irradiation, Dissolution and 
Column Separation 
Targets were constructed by placing a natural 
chromium pellet (99.999% pure, approximately 750 
mg, GFS Chemicals) on the center of a 19 mm 
diameter 2 mm thick silver disc (>99.9% pure, 
Noble Metals, Sarasota, FL) before being folded 
between niobium foil and hydraulically pressed with 
a force of approximately 30 kN for ten seconds. This 
force was sufficient to imbed the chromium metal 
into the silver disc without compromising the 
integrity of the rear target face. These targets were 
irradiated by 16 MeV protons (GE PETtrace) with 
beam currents up to 60 µA. 
Following irradiation, targets were etched by 
2 mL of HCl (32-35%, Optima, VWR) at 75 °C for 
one hour, or until cessation of bubbling (typically 
400 mg of the 750 mg Cr target was dissolved by 
this procedure). The solution was quantitatively 
transferred to a large centrifuge tube using a 47.5 
mL rinse of ethanol (molecular biology grade, 
Sigma-Aldrich). To this solution, 0.5 mL of HCl was 
added resulting in a final target solution of 50 mL. 
 Three columns were constructed, each 
containing approximately 250 mg of dry AG-1x8 
strong anion exchange resin (Bio-Rad Laboratories) 
and were equilibrated and rinsed with 10 mL of 97:3 
ethanol-HCl.  The 50 mL of target solution was 
passed through the first column trapping the 
52
Mn 
and letting the bulk 
nat
Cr pass through. After rinsing 
with 10 mL of 97:3 ethanol--HCl the activity was 
eluted in 1 mL of 6 M HCl. The eluted volume was 
diluted to 50 mL with ethanol, and then loaded on 
the second column. After rinsing, the activity was 
again eluted in 1 mL of 6M HCl and taken up to 50 
mL with ethanol. With the activity loaded onto the 
third and final purification column, the column was 
rinsed, dried with air, and the activity was eluted in 
approximately 1 mL of 0.1 M of HCl. Due to 
mobile-phase retention in the resin, invariably the 
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final elution contained ethanol. It should be noted 
that for some labeling procedures, the eluted product 
should be dried down and reconstituted in 0.1M HCl 
or an appropriate buffer.  
 
Trace Metal Analysis, and DOTA Chelation 
An aliquot of 
52
Mn from each production was taken 
to dryness under vacuum and reconstituted in a 
known volume of 0.1 M HCl. Trace concentrations 
of Cr, Mn, Fe, Co, Ni, Cu, and Zn were measured by 
microwave plasma atomic emission spectrometry 
(MP-AES, Agilent). Total metal impurity load for 
each production was calculated by dividing the 
sample masses by the fraction of the total activity 
used for this assay.  
For chelation assays, 200 µl of 
52
Mn activity 
in 0.1 M HCl was added to 600 µl of pH 4.5, 0.25 M 
NaOAc buffer. Vials containing 100 µl of increasing 
DOTA (Macrocyclics Inc.) concentrations were 
prepared ranging from 0 µg/ml to 10 µg/ml in water. 
A 100 µl aliquot of the buffered activity solution 
was added to each DOTA vial. Vials were vortexed, 
and left to complex at room temperature for one 
hour. Each sample was spotted on a thin layer 
chromatography (TLC) silica plate (60G F254, 
Merck KGaA) and was run with 0.25 M NH4OH 
mobile phase. This method left unbound activity at 
the origin and moved 
52
Mn-DOTA with the mobile 
phase. RadioTLC’s were quantified by phosphor-
storage plate autoradiography (Cyclone Plus, Perkin 
Elmer Inc.). 
 
Preparation of the “Free 52Mn2+”injections 
Eluted 
52
Mn fractions were taken to dryness under 
reduced atmosphere at 70 °C to remove acidity and 
EtOH contamination. 
52
MnCl2 injections were 
prepared by reconstituting the dried 
52
Mn in 
phosphate-buffered saline and 
52
Mn-Acetate 
injections were prepared by reconstituting the dried 
52
Mn in pH 7.5 0.1 M NaOAc.  
 
DOTA-TRC105 Conjugation and 
52
Mn Labeling 
A solution containing TRC105 was adjusted to pH 
8.5-9.0 with 0.1 M Na2CO3. p-SCN-Bn-DOTA 
(Macrocyclics) previously dissolved in DMSO was 
added to this solution in a 25:1 (DOTA : TRC105) 
molar ratio. Following this addition, the pH was 
measured and adjusted to pH 8.5-9.0 with Na2CO3. 
The conjugation reaction was allowed two hours to 
complete at room temperature before DOTA-
TRC105 was purified by size exclusion 
chromatography (PD-10, GE-Healthcare) using 
phosphate-buffered saline (PBS) mobile phase.  
  75-110 MBq of 
52
Mn in ~200 µl 0.1 M HCl 
was added to 500 µl 0.1 M pH 4.5 NaOAc. To 
determine the appropriate quantity of DOTA-
TRC105, labeling was initially tested with 2.7, 6.8, 
13.5 and 27.0 µg/MBq. 
52
Mn labeling with these 
samples was monitored by radio-TLC using 50 mM 
pH 4.5 ethylenediamineetetraacetic acid (EDTA) 
mobile phase over the course of one hour at room 
temperature. TLC peak discrimination was used to 
distinguish between bound and unbound 
52
Mn, and 
peak integration was used for quantification 
following a background subtraction. 
For animal experiments, 4 µg of DOTA-
TRC105 per MBq 
52
Mn was added to the buffered 
activity solution and allowed to react for 60 minutes 
at 37 °C. After labeling, EDTA was added such that 
the resulting concentration was 1 mM. Labeling 
yield was quantified by radio-TLC, and the 
52
Mn-
DOTA-TRC105 was purified by size exclusion 
chromatography using PBS mobile phase. The 
resulting fraction was collected and passed through a 
0.2 µm syringe filter prior to in vivo experiments.   
 
Murine 4T1 Tumor Cell Line and Animal Model 
4T1 cells were cultured in RPMI 1640 growth 
medium (Invitrogen) with 1x low serum growth 
supplement. During culturing, cells were incubated 
at 37 °C with 5% CO2. Once cells reached 
approximately 75% confluence, they were used for 
in vivo experiments.  
All animal studies were conducted under a 
protocol approved by the University of Wisconsin 
Institutional Animal Care and Use Committee. 
Tumors were established in four- to five-week-old 
female Balb/c mice purchased from Harlan Sprague 
Dawley Inc. by subcutaneous injection of 
approximately 2 x 10
6 
cells, suspended in 100 µl of 
1:1 mixture of RPMI 1640 and Matrigel (BD 
Biosciences), into the front flank of seven mice. 
Tumor sizes were monitored, and mice were used 
for imaging experiments when the diameter of 
tumors reached 5-8 mm (typically 1-2 weeks after 
inoculation).  
 
Imaging and Biodistribution Studies 
Mice were anesthetized with 2% isofluorane and 2.2 
- 4.4 MBq of 
52
Mn-DOTA-TRC105 (n=3), 
52
MnCl2 
(n=2), or 
52
Mn-Acetate (n=2) was injected by tail 
vein in a rapid bolus.  PET/CT imaging was 
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performed (Inveon microPET/CT, Siemens Inc.) at 
five time-points between 4 and 128 hours in the 
52
Mn-DOTA-TRC105 group, and five time-points 
between 4 and 96 hours in the 
52
Mn
2+
 control groups 
with at least 40 million coincident counts per PET 
acquisition. Static images were reconstructed using 
three-dimensional ordered subset expectation 
maximization (OSEM3D).  
 Following the last PET time-point, each 
animal was sacrificed. In addition to a blood draw, 
samples from the following tissues were extracted, 
washed in saline, and weighed: 4T1 tumor, skin, 
muscle, bone (femur, inferior half), heart, lung, liver, 
kidney, spleen, pancreas, stomach, intestine, tail, 
brain, and thyroid. 
52
Mn activity in each sample was 
measured by gamma counting (Wizard 2480, 
PerkinElmer). 
 The results of both PET region of interest (ROI) and 
ex vivo biodistribution quantitative analysis were 
expressed as percent of the injected dose per gram of 
tissue (%ID/g ± SD). 
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Figure 1:  99.999% pure chromium pellet embedded in silver, direct-jet watercooled on the rear target face, 
before (A) and after (B) irradiation by 60 µA of 16 MeV protons for one hour.  
33x13mm (600 x 600 DPI)  
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Figure 2:  Serial maximum intensity projection (MIP) PET images of mice injected with 52Mn-DOTA-TRC105 
and 52MnCl2. Significant thyroid accumulation in the 
52MnCl2images contrasting the lack of uptake in the 
52Mn-DOTA-TRC105 images indicates highly stable DOTA chelation of 52Mn2+ even at late time-points. Note – 
H: Heart, L: Liver, K: Kidneys, T: Tumor, Th: Thyroid.  
161x157mm (300 x 300 DPI)  
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Figure 3:  Time activity curves (TACs) acquired from ROI analysis of PET images obtained in subjects 
injected with 52Mn-DOTA-TRC105 (n = 3) and with Free 52Mn (n = 4). Error bars represent the standard 
deviation, and are displayed one-sided for visual clarity. The Heart/Blood TAC uses an ROI drawn over the 
left ventricle and does not differentiate myocardium from the blood pool.  
153x276mm (300 x 300 DPI)  
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Figure 4:  Ex vivo 52Mn-DOTA-TRC105 (n = 3) and 52MnCl2/
52Mn-acetate (n = 4) biodistribution data 
obtained following the last PET time point. Animals were sacrificed, and tissue samples were isolated, 
washed with saline, dried, weighed, and gamma counted.  
110x142mm (300 x 300 DPI)  
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